[Skip to Navigation]
Comment & Response
August 2014

Making Sense of the Evidence From the Age-Related Eye Disease Study 2 Randomized Clinical Trial—Reply

Author Affiliations
  • 1Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland
  • 2The EMMES Corp, Rockville, Maryland
JAMA Ophthalmol. 2014;132(8):1031-1032. doi:10.1001/jamaophthalmol.2014.2009

In Reply We are in complete agreement with Downie and Keller that the population examined in AREDS21 is different from that of the original AREDS.2 The AREDS formulation was initially tested in persons ranging from those with early AMD to those with late AMD in 1 eye. The final recommendation was to consider the AREDS formulation for persons who are at high risk for developing AMD, persons with intermediate AMD (large drusen in ≥1 eye), or persons with late AMD in 1 eye. There was no effect of the supplements in persons with early AMD.

Add or change institution